# PHARMACEUTICAL 2018

## Lifecore Biomedical INC DE
## Rank 121 of 332



# PHARMACEUTICAL 2018

# Lifecore Biomedical INC DE
# Rank 121 of 332

The relative strengths and weaknesses of Lifecore Biomedical INC DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lifecore Biomedical INC DE compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 112% points.The greatest weakness of Lifecore Biomedical INC DE is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 103% points.

The company's Economic Capital Ratio, given in the ranking table, is 308%, being 56% points above the market average of 252%.

| Input Variable | Value in 1000 USD |
|---|---|
| Assets, Current | 81,280 |
| Cost of Goods Sold | 390,564 |
| Intangible Assets | 54,510 |
| Liabilities, Current | 51,454 |
| Liabilities, Non-Current | 42,299 |
| Other Assets | 89,598 |
| Other Compr. Net Income | 345 |
| Other Expenses | 8,446 |
| Other Liabilities | 36,703 |
| Other Net Income | 1,875 |
| Other Revenues | 469,776 |
| Property and Equipment | 133,220 |
| Research and Development | 9,473 |
| Selling, General and Administrative Expense | 52,491 |

| Output Variable | Value in 1000 USD |
|---|---|
| Assets | 358,608 |
| Liabilities | 130,456 |
| Expenses | 460,974 |
| Revenues | 469,776 |
| Stockholders Equity | 228,152 |
| Net Income | 10,677 |
| Comprehensive Net Income | 10,850 |
| BaseVar | 711,017 |
| ECR before LimitedLiability | 208% |
| Economic Capital Ratio | 308% |